Personal Account
Sana Biotechnology

Sana Biotechnology

Developer of engineered cells intended to be used as medicine for patients

Company website
Foundation year

2018

Close date

2/23/2021

Profitability

36.64%

About

Total Funding 

$700M

Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients.

Recent scientific advances make it possible to reprogram cells in the body or replace damaged cells and tissues, creating a new class of medicines to treat a broad array of diseases.

The company is a team of scientists, clinicians and biotechnology veterans focused on creating an enduring company that makes meaningful medicines and will change the approach in treating diseases.

Number of employees

100-250

Headquarters

Seattle, Washington, United States


2022 © All rights reserved

You can always come to our office to discuss any questions with our manager

Dubai

Sharjah Media City, Sharjah, UAE

USA

500 Delaware ave,
STE 1 #1960 Wilmington, DE, USA

Czech Republic

Czech Republic, Prague, Bilkova 855/19

The investment opportunities posted on this website's Pre-IPO section are private placements of securities that are not traded on the open market, subject to the ownership period requirements, and intended for investors who do not require liquid investments. Investments in private companies may be considered speculative, involving high risk, including the significant loss of investment risk. Investors must be able to afford to lose all their investments.